News & Media

Discover our latest news, innovations and advances in alpha-immunotherapy.

ATONCO IN THE SPOTLIGHT: OUR AMBITION FOR NUCLEAR MEDICINE HIGHLIGHTED

The media outlet L’Usine Nouvelle highlights our innovation strategy and the key role that Framatome / IBA’s future cyclotron in Nantes will play in developing our targeted cancer therapies.

A pioneer in nuclear medicine built on the scientific legacy of Professor Jean-François Chatal in Nantes, Atonco is set to reach a major milestone with the launch of a world first: the Phase 1 clinical trial of its drug candidate ATO-101.

Link to the article: https://www.usinenouvelle.com/energie/nucleaire/elle-va-profiter-du-futur-cyclotron-de-framatome-a-nantes-la-pepite-atonco-veut-revolutionner-la-medecine-nucleaire.QWQRI76TVZIP3K4PSQEVMRXQFA.html